Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy

19 Jan 2026 CW Team

The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio.

The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary.

This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026.

The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets.

Net proceeds will be utilised towards:

Payment to Viatris for acquisition of Biocon Biologics shares

Repayment of debt linked to the acquisition

Funding for redemption of compulsorily convertible debentures held by Biocon Biologics

General corporate purposes

The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025.

Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Biocon Limited has successfully completed a Qualified Institutions Placement (QIP), raising Rs 4.15 billion (approximately USD 460 million) through the issuance of 12,664,585 equity shares at an issue price of Rs 368.35 per share, including a premium of Rs 363.35. The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio. The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary. This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026. The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets. Net proceeds will be utilised towards: Payment to Viatris for acquisition of Biocon Biologics shares Repayment of debt linked to the acquisition Funding for redemption of compulsorily convertible debentures held by Biocon Biologics General corporate purposes The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025. Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.

Real Estate

30 Jul 2026

AI: The New Recruit

From getting ideas to evaluating designs, presenting concepts to clients and tracking projects, artificial intelligence (AI) is helping architects work better and faster.“AI allows architects to spend more time doing what only they can do: think critically, synthesise complexity and design with intent,” says Dikshu C Kukreja, Managing Principal, CP Kukreja Architects. “Every minute reclaimed from repetitive processes can be invested in creativity, contextual understanding, interdisciplinary collaboration and innovation – the qualities that define meaningful architecture.”To read the ..

Real Estate

30 Jul 2026

Redevelopment 2.0

In 2017, Mumbai identified 160,000 ageing buildings due for structural audit. Close to half of these were in the Western Suburbs. Redeveloping the oldest and structurally weakest of these would help unlock new housing, much needed given the city’s growing population density and constant developed area of 437.7 sq km. At 30,600 people per sq km in 2024, Mumbai’s density was almost thrice that of Gurugram, and 60 per cent higher than Bengaluru’s.Essentially, Mumbai’s realty market has demand. It has capital. It has realty development potential.Fast forward to 2026. Mumbai has 1,094 regis..

Technology

30 Jul 2026

Cost intelligence will become a strategic contributor to project success

As India's construction industry accelerates its digital transformation, integrated platforms, AI and connected data are becoming essential to improving cost certainty, project efficiency and sustainability. Ravi Kumar, Sales Director – India, RIB Software India, shares how digital workflows are reshaping project planning, commercial management and decision-making across the construction value chain.India's construction sector is embracing digital technologies at an unprecedented pace. From your perspective, what are the biggest shifts driving this transformation and how is RIB Software enab..